Idexx Laboratories (IDXX) Common Equity (2009 - 2026)

Idexx Laboratories' Common Equity history runs 18 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Common Equity rose 7.46% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 7.46% YoY), while the FY2025 annual figure was $1.6 billion, up 0.63% from the prior year.
• Common Equity was $1.6 billion for Q1 2026 at Idexx Laboratories, down from $1.6 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.6 billion in Q3 2024 to a low of $457.0 million in Q2 2022.
• Historically, Common Equity has averaged $1.2 billion across 5 years, with a median of $1.5 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 38.92% in 2022, then jumped 172.57% in 2023.
• A 5-year view of Common Equity shows it stood at $608.7 million in 2022, then surged by 143.87% to $1.5 billion in 2023, then climbed by 7.46% to $1.6 billion in 2024, then rose by 0.63% to $1.6 billion in 2025, then declined by 3.07% to $1.6 billion in 2026.
• The last three Common Equity figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.